Experimental eczema drug tested in healthy people – but trial halted

NCT ID NCT05288543

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a very early (Phase 1) study to check the safety of an experimental drug called IPG7236, taken as a pill. The study involved 63 healthy adults aged 18 to 55. The goal was to see how the body handles the drug and if it causes side effects, before testing it in people with atopic dermatitis (eczema). The trial was terminated, so its findings may be incomplete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IPG7236 (an experimental oral drug)

What this could lead to

If successful, this early study could pave the way for further testing of IPG7236 as a potential treatment for atopic dermatitis.

What could go wrong

This is a very early Phase 1 trial in healthy volunteers, not patients. The study was terminated, so results may be limited. It is too soon to know if IPG7236 will be safe or effective for treating any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, 2031, Australia